Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL | MicrobiomeTrials← Back to trialsNCT04324112
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2020-10-28Est. Completion: 2026-05-20
Enrollment target: 28 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Hairy Cell Leukemia
Background:
Most people with hairy cell leukemia have a BRAF gene mutation. They can be treated with BRAF inhibitors, d…
Bethesda, United StatesEst. completion Apr 30, 2028
Hairy Cell LeukemiaHairy Cell Leukemia VariantRecurrent Hairy Cell LeukemiaRecurrent Hairy Cell Leukemia Variant
This phase II trial studies how well ibrutinib works in treating patients with hairy cell leukemia that has returned aft…
Bethesda, United StatesEst. completion Dec 31, 2029